Hydrogen therapy: a future option in critical care?

PubWeight™: 0.79‹?›

🔗 View Article (PMID 22425856)

Published in Crit Care Med on April 01, 2012

Authors

Rüdiger Hardeland

Articles by these authors

Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res (2003) 1.23

Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J Neuroimmunol (2005) 1.14

Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Neurotox Res (2012) 1.04

Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res (2006) 1.04

The changing biological roles of melatonin during evolution: from an antioxidant to signals of darkness, sexual selection and fitness. Biol Rev Camb Philos Soc (2009) 0.99

Antioxidant properties of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep (2003) 0.98

Melatonin's unique radical scavenging properties - roles of its functional substituents as revealed by a comparison with its structural analogs. J Pineal Res (2002) 0.95

Fine-tuning the amphiphilicity: a crucial parameter in the design of potent alpha-phenyl-N-tert-butylnitrone analogues. J Med Chem (2007) 0.94

Mechanistic and comparative studies of melatonin and classic antioxidants in terms of their interactions with the ABTS cation radical. J Pineal Res (2003) 0.93

Fluorinated amphiphilic amino acid derivatives as antioxidant carriers: a new class of protective agents. J Med Chem (2006) 0.91

Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection. Ther Adv Neurol Disord (2011) 0.90

Interactions of melatonin and its metabolites with the ABTS cation radical: extension of the radical scavenger cascade and formation of a novel class of oxidation products, C2-substituted 3-indolinones. J Pineal Res (2006) 0.88

Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther (2009) 0.87

Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. Nat Clin Pract Neurol (2007) 0.87

Measurement of melatonin in body fluids: standards, protocols and procedures. Childs Nerv Syst (2010) 0.85

The melatonin metabolite N-acetyl-5-methoxykynuramine is a potent singlet oxygen scavenger. J Pineal Res (2008) 0.85

Mitochondrial medicine: neuroprotection and life extension by the new amphiphilic nitrone LPBNAH acting as a highly potent antioxidant agent. J Neurochem (2005) 0.85

Reactions of the melatonin metabolite AMK (N1-acetyl-5-methoxykynuramine) with reactive nitrogen species: formation of novel compounds, 3-acetamidomethyl-6-methoxycinnolinone and 3-nitro-AMK. J Pineal Res (2005) 0.82

Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies. Neuroendocrinology (2016) 0.82

Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients. J Pineal Res (2002) 0.81

Melatonin receptor genes in vertebrates. Int J Mol Sci (2013) 0.80

NO scavenging by 3-hydroxyanthranilic acid and 3-hydroxykynurenine: N-nitrosation leads via oxadiazoles to o-quinone diazides. Nitric Oxide (2008) 0.80

Amphiphilic amide nitrones: a new class of protective agents acting as modifiers of mitochondrial metabolism. J Med Chem (2010) 0.80

Antioxidant activity in Spalax ehrenbergi: a possible adaptation to underground stress. J Comp Physiol A Neuroethol Sens Neural Behav Physiol (2006) 0.79

C5a anaphylatoxin as a product of complement activation up-regulates the complement inhibitory factor H in rat Kupffer cells. Eur J Immunol (2004) 0.78

Effects of delta-aminolevulinic acid and melatonin in the harderian gland of female Syrian hamsters. Free Radic Biol Med (2002) 0.78

Photocatalytic actions of the pesticide metabolite 2-hydroxyquinoxaline: destruction of antioxidant vitamins and biogenic amines - implications of organic redox cycling. Redox Rep (2004) 0.78

Pharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applications. J Cent Nerv Syst Dis (2011) 0.77

Toxicity of the quinalphos metabolite 2-hydroxyquinoxaline: growth inhibition, induction of oxidative stress, and genotoxicity in test organisms. Environ Toxicol (2007) 0.77

Melatonin protects against delta-aminolevulinic acid-induced oxidative damage in male Syrian hamster Harderian glands. Int J Biochem Cell Biol (2002) 0.77

Photocatalytic mechanisms of indoleamine destruction by the quinalphos metabolite 2-hydroxyquinoxaline: a study on melatonin and its precursors serotonin and N-acetylserotonin. J Environ Sci Health B (2007) 0.77

Novel pathway for N1-acetyl-5-methoxykynuramine: UVB-induced liberation of carbon monoxide from precursor N1-acetyl-N2-formyl-5-methoxykynuramine. J Pineal Res (2008) 0.76

Reactions of the melatonin metabolite N(1)-acetyl-5-methoxykynuramine with carbamoyl phosphate and related compounds. J Pineal Res (2009) 0.76

Reactions of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK) with the ABTS cation radical: identification of new oxidation products. Redox Rep (2006) 0.76

A Comparison of B16 Melanoma Cells and 3T3 Fibroblasts Concerning Cell Viability and ROS Production in the Presence of Melatonin, Tested Over a Wide Range of Concentrations. Int J Mol Sci (2013) 0.76

Reactions of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK) with the tyrosine side-chain fragment, 4-ethylphenol. Redox Rep (2008) 0.75

Stunted Growth. Proceedings of the 23rd Aschauer Soiree, Held at Aschauhof, Germany, November 7th 2015. Pediatr Endocrinol Rev (2016) 0.75